Antibodies targeting PD1/PD-L1 are emerging as effective cancer immunotherapies, however, not all patients with PD-L1 expression respond to the treatment.

This phase I clinical trial enrolls patients with advanced or metastatic solid tumors who progressed on or after standard treatments. In the dose escalation phase, patients without preselection of tumor CLDN18.2 expression were given increasing doses of TST001 intravenously every 3 weeks (Q3W) using a 3+3 design.

In normal conditions, Claudin (CLDN)18.2 is a tight junction protein with expression strictly confined to differentiated epithelial cells in gastric mucosa.

MSB2311注射液在晚期多線治療失敗的實體瘤和淋巴瘤受試者中表現出較好的抗腫瘤活性，安全性和耐受性良好，值得開展進一步的臨床研究。

在中國晚期腫瘤患者中，MSB0254注射液顯示出良好的安全性、耐受性和一定的抗腫瘤療效。

MSB2311 is a novel humanized PD-L1 antibody with a unique pH-dependent antigen binding property that enables intra-tumor recycling and potentiates tumor penetration.